• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

异柠檬酸脱氢酶(IDH)突变亚组状态与肝内胆管癌的肿瘤内异质性及肿瘤微环境相关。

IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.

作者信息

Xiang Xiao, Liu Ziyang, Zhang Chong, Li Zhao, Gao Jie, Zhang Changkun, Cao Qi, Cheng Jinghui, Liu Hengkang, Chen Dingbao, Cheng Qian, Zhang Ning, Xue Ruidong, Bai Fan, Zhu Jiye

机构信息

Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing Key Surgical Basic Research Laboratory of Liver Cirrhosis and Liver Cancer, Beijing, 100044, China.

Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing, 100871, China.

出版信息

Adv Sci (Weinh). 2021 Sep;8(17):e2101230. doi: 10.1002/advs.202101230. Epub 2021 Jul 11.

DOI:10.1002/advs.202101230
PMID:34250753
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8425914/
Abstract

Intrahepatic cholangiocarcinoma (ICC) is highly heterogeneous. Here, the authors perform exome sequencing and bulk RNA sequencing on 73 tumor regions from 14 ICC patients to portray the multi-faceted intratumor heterogeneity (ITH) landscape of ICC. The authors show that ITH is highly concordant across genomic, transcriptomic, and immune levels. Comparison of these data to 8 published datasets reveals significantly higher degrees of ITH in ICC than hepatocellular carcinoma. Remarkably, the authors find that high-ITH tumors highly overlap with the IDH (isocitrate dehydrogenase)-mutant subgroup (IDH-SG), comprising of IDH-mutated tumors and IDH-like tumors, that is, those IDH-wildtype tumors that exhibit similar molecular profiles to the IDH-mutated ones. Furthermore, IDH-SG exhibits less T cell infiltration and lower T cell cytotoxicity, indicating a colder tumor microenvironment (TME). The higher ITH and colder TME of IDH-SG are successfully validated by single-cell RNA sequencing on 17 503 cells from 4 patients. Collectively, the study shows that IDH mutant subgroup status, rather than IDH mutation alone, is associated with ITH and the TME of ICC tumors. The results highlight that IDH-like patients may also benefit from IDH targeted therapies and provide important implications for the diagnosis and treatment of ICC.

摘要

肝内胆管癌(ICC)具有高度异质性。在此,作者对14例ICC患者的73个肿瘤区域进行了外显子组测序和批量RNA测序,以描绘ICC多层面的肿瘤内异质性(ITH)景观。作者表明,ITH在基因组、转录组和免疫水平上高度一致。将这些数据与8个已发表的数据集进行比较,发现ICC中的ITH程度明显高于肝细胞癌。值得注意的是,作者发现高ITH肿瘤与异柠檬酸脱氢酶(IDH)突变亚组(IDH-SG)高度重叠,该亚组由IDH突变肿瘤和IDH样肿瘤组成,即那些与IDH突变肿瘤表现出相似分子特征的IDH野生型肿瘤。此外,IDH-SG表现出较少的T细胞浸润和较低的T细胞细胞毒性,表明肿瘤微环境(TME)较冷。通过对4例患者的17503个细胞进行单细胞RNA测序,成功验证了IDH-SG较高的ITH和较冷的TME。总体而言,该研究表明,IDH突变亚组状态而非单独的IDH突变与ICC肿瘤的ITH和TME相关。结果突出表明,IDH样患者也可能从IDH靶向治疗中获益,并为ICC的诊断和治疗提供重要启示。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7f/8425914/850f1d7ffbcf/ADVS-8-2101230-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7f/8425914/458ebd301b51/ADVS-8-2101230-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7f/8425914/c563aaf62885/ADVS-8-2101230-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7f/8425914/1bd388afc458/ADVS-8-2101230-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7f/8425914/cbe1c1881955/ADVS-8-2101230-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7f/8425914/8ac7cf1b46c6/ADVS-8-2101230-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7f/8425914/a9136b04feaa/ADVS-8-2101230-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7f/8425914/850f1d7ffbcf/ADVS-8-2101230-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7f/8425914/458ebd301b51/ADVS-8-2101230-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7f/8425914/c563aaf62885/ADVS-8-2101230-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7f/8425914/1bd388afc458/ADVS-8-2101230-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7f/8425914/cbe1c1881955/ADVS-8-2101230-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7f/8425914/8ac7cf1b46c6/ADVS-8-2101230-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7f/8425914/a9136b04feaa/ADVS-8-2101230-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7f/8425914/850f1d7ffbcf/ADVS-8-2101230-g006.jpg

相似文献

1
IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.异柠檬酸脱氢酶(IDH)突变亚组状态与肝内胆管癌的肿瘤内异质性及肿瘤微环境相关。
Adv Sci (Weinh). 2021 Sep;8(17):e2101230. doi: 10.1002/advs.202101230. Epub 2021 Jul 11.
2
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.晚期异柠檬酸脱氢酶(IDH)突变型和IDH野生型肝内胆管癌患者的预后及临床病理特征
Oncologist. 2015 Sep;20(9):1019-27. doi: 10.1634/theoncologist.2015-0210. Epub 2015 Aug 5.
3
Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.肝内胆管癌的空间和时间克隆进化。
J Hepatol. 2018 Jul;69(1):89-98. doi: 10.1016/j.jhep.2018.02.029. Epub 2018 Mar 16.
4
Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma.肝内胆管癌中差异型异柠檬酸脱氢酶 1 和异柠檬酸脱氢酶 2 突变相关图谱。
Oncologist. 2024 Aug 5;29(8):e1061-e1072. doi: 10.1093/oncolo/oyae132.
5
Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma.肝内胆管癌中 IDH1 突变与独特的组织形态学特征相关。
Hum Pathol. 2019 Sep;91:19-25. doi: 10.1016/j.humpath.2019.05.002. Epub 2019 May 21.
6
IDH mutations in liver cell plasticity and biliary cancer.异柠檬酸脱氢酶(IDH)突变与肝细胞可塑性及胆管癌
Cell Cycle. 2014;13(20):3176-82. doi: 10.4161/15384101.2014.965054.
7
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.胆管癌的综合基因组分析确定了不同的异柠檬酸脱氢酶(IDH)突变分子谱。
Cell Rep. 2017 Mar 14;18(11):2780-2794. doi: 10.1016/j.celrep.2017.02.033.
8
Multiomic Analysis Reveals Comprehensive Tumor Heterogeneity and Distinct Immune Subtypes in Multifocal Intrahepatic Cholangiocarcinoma.多组学分析揭示多灶性肝内胆管癌的全面肿瘤异质性和不同免疫亚型
Clin Cancer Res. 2022 May 2;28(9):1896-1910. doi: 10.1158/1078-0432.CCR-21-1157.
9
Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.异柠檬酸脱氢酶 1 突变使肝内胆管癌对 BET 抑制剂 JQ1 敏感。
Cancer Sci. 2018 Nov;109(11):3602-3610. doi: 10.1111/cas.13784. Epub 2018 Sep 17.
10
Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.异柠檬酸脱氢酶突变型胆管癌:自然史与临床结局
JCO Precis Oncol. 2022 Jan;6:e2100156. doi: 10.1200/PO.21.00156.

引用本文的文献

1
Molecular and Histological Profiles and Relevant Imaging Signatures of Intrahepatic Cholangiocarcinoma.肝内胆管癌的分子和组织学特征及相关影像学特征
J Clin Transl Hepatol. 2025 Jun 28;13(6):504-515. doi: 10.14218/JCTH.2024.00410. Epub 2025 Apr 30.
2
Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets.软骨肉瘤的基因组特征揭示了潜在的治疗靶点。
JCO Precis Oncol. 2025 Mar;9:e2400592. doi: 10.1200/PO-24-00592. Epub 2025 Mar 21.
3
Evaluation of an Mutation FastTrack Assay for Patients with Cholangiocarcinoma.

本文引用的文献

1
Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma.肿瘤内免疫异质性是肝癌演进和进展的一个标志。
Nat Commun. 2021 Jan 11;12(1):227. doi: 10.1038/s41467-020-20171-7.
2
Turning Cold into Hot: Firing up the Tumor Microenvironment.化寒为热:点燃肿瘤微环境
Trends Cancer. 2020 Jul;6(7):605-618. doi: 10.1016/j.trecan.2020.02.022. Epub 2020 Mar 21.
3
Cholangiocarcinoma 2020: the next horizon in mechanisms and management.胆管癌 2020:机制和管理的新前沿。
胆管癌患者的一种突变快速检测方法的评估
Cancers (Basel). 2025 Feb 27;17(5):820. doi: 10.3390/cancers17050820.
4
IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies.异柠檬酸脱氢酶(IDH)突变型胆管癌:发病机制、治疗及未来疗法
Curr Oncol. 2025 Jan 17;32(1):44. doi: 10.3390/curroncol32010044.
5
Single-Cell and Spatial Transcriptomics Delineate the Microstructure and Immune Landscape of Intrahepatic Cholangiocarcinoma in the Leading-Edge Area.单细胞和空间转录组学描绘肝内胆管癌前缘区域的微观结构和免疫图谱
Adv Sci (Weinh). 2025 Feb;12(7):e2412740. doi: 10.1002/advs.202412740. Epub 2024 Dec 24.
6
Unveil Intrahepatic Cholangiocarcinoma Heterogeneity through the Lens of Omics and Multi-Omics Approaches.通过组学和多组学方法揭示肝内胆管癌的异质性
Cancers (Basel). 2024 Aug 20;16(16):2889. doi: 10.3390/cancers16162889.
7
HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment.HER2 扩增型肝内胆管癌具有高突变负担和 T 细胞耗竭微环境。
J Cancer Res Clin Oncol. 2024 Aug 28;150(8):403. doi: 10.1007/s00432-024-05894-0.
8
Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions.治疗胆管癌冷肿瘤的策略:核心概念和未来方向。
Clin Exp Med. 2024 Aug 14;24(1):193. doi: 10.1007/s10238-024-01460-7.
9
Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives.靶向实体瘤中的异柠檬酸脱氢酶(IDH):当前证据与未来展望
Cancers (Basel). 2024 Aug 2;16(15):2752. doi: 10.3390/cancers16152752.
10
Molecular Targeting of the Isocitrate Dehydrogenase Pathway and the Implications for Cancer Therapy.靶向异柠檬酸脱氢酶代谢途径及其在癌症治疗中的意义。
Int J Mol Sci. 2024 Jul 4;25(13):7337. doi: 10.3390/ijms25137337.
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588. doi: 10.1038/s41575-020-0310-z. Epub 2020 Jun 30.
4
Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells.脑肿瘤微环境景观的剖析揭示了免疫细胞的疾病特异性改变。
Cell. 2020 Jun 25;181(7):1643-1660.e17. doi: 10.1016/j.cell.2020.05.007. Epub 2020 May 28.
5
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.ivosidenib 治疗 IDH1 突变、化疗耐药性胆管癌(ClarIDHy):一项多中心、随机、双盲、安慰剂对照、3 期研究。
Lancet Oncol. 2020 Jun;21(6):796-807. doi: 10.1016/S1470-2045(20)30157-1. Epub 2020 May 13.
6
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
7
Mapping the spreading routes of lymphatic metastases in human colorectal cancer.绘制人类结直肠癌淋巴转移的扩散路径图。
Nat Commun. 2020 Apr 24;11(1):1993. doi: 10.1038/s41467-020-15886-6.
8
Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.IDH1/2 突变和其他常见突变在大导管型和小导管型肝内胆管细胞癌中的不同临床和预后意义。
BMC Cancer. 2020 Apr 15;20(1):318. doi: 10.1186/s12885-020-06804-6.
9
CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes.CellPhoneDB:从多亚基配体-受体复合物的综合表达推断细胞间通讯。
Nat Protoc. 2020 Apr;15(4):1484-1506. doi: 10.1038/s41596-020-0292-x. Epub 2020 Feb 26.
10
Intratumoral heterogeneity and clonal evolution in liver cancer.肝癌中的肿瘤内异质性和克隆进化。
Nat Commun. 2020 Jan 15;11(1):291. doi: 10.1038/s41467-019-14050-z.